HAE
Haemonetics Corporation
Price Chart
Latest Quote
$72.60
-0.18 (-0.25%)
Current Price
| Previous Close | $72.78 |
| Open | $73.60 |
| Day High | $74.98 |
| Day Low | $72.29 |
| Volume | 149,710 |
Stock Information
| Shares Outstanding | 45.45M |
| Total Debt | $1.27B |
| Cash Equivalents | $246.26M |
| Revenue | $1.33B |
| Net Income | $97.31M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $3.30B |
| P/E Ratio | 35.41 |
| EPS (TTM) | $2.05 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.34B |
| Sales | $1.33B |
| Income | $97.31M |
| Book/sh | $17.60 |
| Cash/sh | $5.42 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 1.64 |
| Current Ratio | 2.95 |
| Debt/Eq | 160.08 |
Returns & Margins
| ROA | 6.49% |
| ROE | 12.03% |
| Gross Margin | 59.43% |
| Operating Margin | 13.88% |
| Profit Margin | 7.29% |
Ownership
| Insider Ownership | 1.25% |
| Institutional Ownership | 108.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.61 |
| PEG | 1.16 |
| P/S | 2.47 |
| P/B | 4.13 |
Analyst Data
| Recommendation | buy |
| Target Price | $85.20 |
Technical Indicators
| SMA20 | $72.46 |
| SMA50 | $64.24 |
| SMA200 | $64.09 |
| RSI | 63.67 |
| ATR | 3.2873 |
| Shares Float | 44.86M |
| Short Float | 8.82% |
| Short Ratio | 3.05 |
| Volatility | 0.54 |
| Rel Volume | 0.14 |
Performance History
| Week | -2.46% |
| Month | +10.86% |
| Quarter | +28.13% |
| 6 Months | -9.49% |
| YTD | -9.23% |
| Year | +0.74% |
| 3 Years | -13.43% |
| 5 Years | +23.66% |
| 10 Years | +152.43% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $72.60 | 149,710 |
| 2026-06-23 | $72.78 | 625,100 |
| 2026-06-22 | $72.53 | 1,171,900 |
| 2026-06-18 | $74.17 | 887,700 |
| 2026-06-17 | $72.73 | 1,252,700 |
| 2026-06-16 | $74.43 | 1,322,000 |
| 2026-06-15 | $76.91 | 886,400 |
| 2026-06-12 | $78.20 | 1,198,300 |
| 2026-06-11 | $79.84 | 1,749,700 |
| 2026-06-10 | $78.80 | 1,006,900 |
| 2026-06-09 | $78.71 | 1,888,100 |
| 2026-06-08 | $74.88 | 1,343,200 |
| 2026-06-05 | $71.28 | 604,800 |
| 2026-06-04 | $69.85 | 1,215,500 |
| 2026-06-03 | $65.88 | 743,800 |
| 2026-06-02 | $66.37 | 921,800 |
| 2026-06-01 | $67.22 | 735,900 |
| 2026-05-29 | $67.81 | 942,500 |
| 2026-05-28 | $67.04 | 1,014,300 |
| 2026-05-27 | $67.16 | 1,138,200 |
| 2026-05-26 | $66.84 | 1,049,400 |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
đ° Latest News
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment
Simply Wall St. âĸ 2026-06-09T16:10:42Z
Sector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires âĸ 2026-06-05T19:49:02ZWhy Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next
Simply Wall St. âĸ 2026-05-25T13:14:59Z
Haemonetics (HAE) Stock Is Up, What You Need To Know
StockStory âĸ 2026-05-23T21:16:55Z
Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)
StockStory âĸ 2026-05-23T01:48:55Z
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Zacks âĸ 2026-05-22T13:15:01Z
Does Haemonetics (HAE) Have Enduring Growth Potential?
Insider Monkey âĸ 2026-05-21T14:48:24Z
3 Russell 2000 Stocks That Concern Us
StockStory âĸ 2026-05-20T12:12:55Z
3 Small-Cap Stocks Weâre Skeptical Of
StockStory âĸ 2026-05-19T10:20:55Z
Is the Options Market Predicting a Spike in Haemonetics Stock?
Zacks âĸ 2026-05-13T13:22:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $478,722,000 | $544,541,000 | $552,323,000 | $492,896,000 |
| Cost Of Revenue | $546,441,000 | $611,866,000 | $617,507,000 | $553,563,000 |
| Total Revenue | $1,334,027,000 | $1,360,824,000 | $1,309,055,000 | $1,168,660,000 |
| Operating Revenue | $1,334,027,000 | $1,360,824,000 | $1,309,055,000 | $1,168,660,000 |
| Expenses | ||||
| Interest Expense | $28,704,000 | $9,746,000 | $13,018,000 | $14,630,000 |
| Total Expenses | $1,092,626,000 | $1,159,638,000 | $1,133,753,000 | $1,013,009,000 |
| Other Income Expense | $-84,667,000 | $20,631,000 | $-10,419,000 | $382,000 |
| Net Non Operating Interest Income Expense | $-28,704,000 | $-9,746,000 | $-13,018,000 | $-14,630,000 |
| Interest Expense Non Operating | $28,704,000 | $9,746,000 | $13,018,000 | $14,630,000 |
| Operating Expense | $546,185,000 | $547,772,000 | $516,246,000 | $459,446,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Net Interest Income | $-28,704,000 | $-9,746,000 | $-13,018,000 | $-14,630,000 |
| Normalized Income | $161,654,920 | $151,359,879 | $125,622,306 | $115,089,288 |
| Net Income From Continuing And Discontinued Operation | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Total Operating Income As Reported | $156,734,000 | $221,817,000 | $164,883,000 | $156,033,000 |
| Net Income Common Stockholders | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Net Income | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Net Income Including Noncontrolling Interests | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Net Income Continuous Operations | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Pretax Income | $128,030,000 | $212,071,000 | $151,865,000 | $141,403,000 |
| Special Income Charges | $-84,667,000 | $20,631,000 | $-10,419,000 | $382,000 |
| Operating Income | $241,401,000 | $201,186,000 | $175,302,000 | $155,651,000 |
| Depreciation Amortization Depletion Income Statement | $43,998,000 | $48,261,000 | $32,031,000 | $32,640,000 |
| Depreciation And Amortization In Income Statement | $43,998,000 | $48,261,000 | $32,031,000 | $32,640,000 |
| Amortization Of Intangibles Income Statement | $43,998,000 | $48,261,000 | $32,031,000 | $32,640,000 |
| Gross Profit | $787,586,000 | $748,958,000 | $691,548,000 | $615,097,000 |
| Per Share | ||||
| Diluted EPS | $2.05 | $3.31 | $2.29 | $2.24 |
| Basic EPS | $2.06 | $3.33 | $2.32 | $2.27 |
| Other | ||||
| Tax Effect Of Unusual Items | $-20,320,080 | $4,311,879 | $-2,354,694 | $70,288 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $353,118,000 | $316,772,000 | $272,517,000 | $248,958,000 |
| Total Unusual Items | $-84,667,000 | $20,631,000 | $-10,419,000 | $382,000 |
| Total Unusual Items Excluding Goodwill | $-84,667,000 | $20,631,000 | $-10,419,000 | $382,000 |
| Reconciled Depreciation | $111,717,000 | $115,586,000 | $97,215,000 | $93,307,000 |
| EBITDA (Bullshit earnings) | $268,451,000 | $337,403,000 | $262,098,000 | $249,340,000 |
| EBIT | $156,734,000 | $221,817,000 | $164,883,000 | $156,033,000 |
| Diluted Average Shares | $47,354,000 | $50,730,000 | $51,397,000 | $51,420,000 |
| Basic Average Shares | $47,179,000 | $50,330,000 | $50,706,000 | $50,783,000 |
| Diluted NI Availto Com Stockholders | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Tax Provision | $30,722,000 | $44,392,000 | $34,307,000 | $26,002,000 |
| Impairment Of Capital Assets | $86,546,000 | $2,391,000 | $10,419,000 | $0 |
| Restructuring And Mergern Acquisition | $-1,879,000 | $-23,022,000 | $0 | $0 |
| Amortization | $43,998,000 | $48,261,000 | $32,031,000 | $32,640,000 |
| Research And Development | $59,766,000 | $62,722,000 | $54,435,000 | $50,131,000 |
| Selling General And Administration | $442,421,000 | $436,789,000 | $429,780,000 | $376,675,000 |
| Gain On Sale Of Business | - | $0 | $2,000,000 | $382,000 |
| Write Off | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-307,703,000 | $-239,175,000 | $-11,240,000 | $75,995,000 |
| Total Assets | $2,395,925,000 | $2,450,948,000 | $2,195,591,000 | $1,934,825,000 |
| Total Non Current Assets | $1,561,046,000 | $1,515,972,000 | $1,426,688,000 | $1,165,103,000 |
| Other Non Current Assets | $141,741,000 | $164,106,000 | $136,388,000 | $106,975,000 |
| Non Current Deferred Assets | $9,521,000 | $7,803,000 | $7,739,000 | $5,241,000 |
| Non Current Deferred Taxes Assets | $9,521,000 | $7,803,000 | $7,739,000 | $5,241,000 |
| Goodwill And Other Intangible Assets | $1,104,023,000 | $1,060,011,000 | $971,199,000 | $742,002,000 |
| Other Intangible Assets | $447,655,000 | $455,742,000 | $406,117,000 | $275,771,000 |
| Current Assets | $834,879,000 | $934,975,000 | $768,903,000 | $769,722,000 |
| Other Current Assets | $66,214,000 | $60,414,000 | $66,339,000 | $46,735,000 |
| Inventory | $306,370,000 | $365,141,000 | $317,202,000 | $259,379,000 |
| Receivables | $216,855,000 | $202,657,000 | $206,562,000 | $179,142,000 |
| Accounts Receivable | $216,855,000 | $202,657,000 | $206,562,000 | $179,142,000 |
| Allowance For Doubtful Accounts Receivable | $-3,693,000 | $-6,300,000 | $-5,695,000 | $-4,932,000 |
| Gross Accounts Receivable | $220,548,000 | $208,957,000 | $212,257,000 | $184,074,000 |
| Cash Cash Equivalents And Short Term Investments | $245,440,000 | $306,763,000 | $178,800,000 | $284,466,000 |
| Cash And Cash Equivalents | $245,440,000 | $306,763,000 | $178,800,000 | $284,466,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $979,140,000 | $918,025,000 | $628,993,000 | $481,420,000 |
| Total Debt | $1,224,580,000 | $1,224,788,000 | $807,793,000 | $765,886,000 |
| Long Term Debt And Capital Lease Obligation | $1,219,565,000 | $921,230,000 | $797,564,000 | $754,102,000 |
| Long Term Debt | $1,219,565,000 | $921,230,000 | $797,564,000 | $754,102,000 |
| Current Debt And Capital Lease Obligation | $5,015,000 | $303,558,000 | $10,229,000 | $11,784,000 |
| Current Debt | $5,015,000 | $303,558,000 | $10,229,000 | $11,784,000 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,599,605,000 | $1,630,112,000 | $1,235,632,000 | $1,116,828,000 |
| Total Non Current Liabilities Net Minority Interest | $1,317,006,000 | $1,051,999,000 | $935,249,000 | $865,012,000 |
| Other Non Current Liabilities | $59,393,000 | $68,194,000 | $75,041,000 | $74,715,000 |
| Non Current Deferred Liabilities | $38,048,000 | $62,575,000 | $62,644,000 | $36,195,000 |
| Non Current Deferred Taxes Liabilities | $38,048,000 | $62,575,000 | $62,644,000 | $36,195,000 |
| Current Liabilities | $282,599,000 | $578,113,000 | $300,383,000 | $251,816,000 |
| Other Current Liabilities | $116,027,000 | $104,785,000 | $104,846,000 | $81,419,000 |
| Current Deferred Liabilities | $42,310,000 | $43,348,000 | $31,242,000 | $30,209,000 |
| Payables And Accrued Expenses | $119,247,000 | $126,422,000 | $154,066,000 | $128,404,000 |
| Payables | $51,056,000 | $66,999,000 | $73,358,000 | $63,929,000 |
| Accounts Payable | $51,056,000 | $66,999,000 | $73,358,000 | $63,929,000 |
| Total Tax Payable | - | - | - | - |
| Derivative Product Liabilities | - | - | - | - |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $796,320,000 | $820,836,000 | $959,959,000 | $817,997,000 |
| Total Equity Gross Minority Interest | $796,320,000 | $820,836,000 | $959,959,000 | $817,997,000 |
| Stockholders Equity | $796,320,000 | $820,836,000 | $959,959,000 | $817,997,000 |
| Gains Losses Not Affecting Retained Earnings | $-37,614,000 | $-55,084,000 | $-35,632,000 | $-30,381,000 |
| Other Equity Adjustments | $-37,614,000 | $-55,084,000 | $-35,632,000 | $-30,381,000 |
| Retained Earnings | $279,344,000 | $352,174,000 | $360,456,000 | $253,168,000 |
| Other | ||||
| Ordinary Shares Number | $45,252,667 | $48,215,899 | $50,787,859 | $50,448,519 |
| Share Issued | $45,252,667 | $48,215,899 | $50,787,859 | $50,448,519 |
| Tangible Book Value | $-307,703,000 | $-239,175,000 | $-11,240,000 | $75,995,000 |
| Invested Capital | $2,020,900,000 | $2,045,624,000 | $1,767,752,000 | $1,583,883,000 |
| Working Capital | $552,280,000 | $356,862,000 | $468,520,000 | $517,906,000 |
| Total Capitalization | $2,015,885,000 | $1,742,066,000 | $1,757,523,000 | $1,572,099,000 |
| Additional Paid In Capital | $554,137,000 | $523,264,000 | $634,627,000 | $594,706,000 |
| Capital Stock | $453,000 | $482,000 | $508,000 | $504,000 |
| Common Stock | $453,000 | $482,000 | $508,000 | $504,000 |
| Current Deferred Revenue | $42,310,000 | $43,348,000 | $31,242,000 | $30,209,000 |
| Current Accrued Expenses | $68,191,000 | $59,423,000 | $80,708,000 | $64,475,000 |
| Goodwill | $656,368,000 | $604,269,000 | $565,082,000 | $466,231,000 |
| Net PPE | $305,761,000 | $284,052,000 | $311,362,000 | $310,885,000 |
| Accumulated Depreciation | $-536,068,000 | $-553,142,000 | $-647,815,000 | $-633,330,000 |
| Gross PPE | $841,829,000 | $837,194,000 | $959,177,000 | $944,215,000 |
| Construction In Progress | $29,943,000 | $22,229,000 | $39,694,000 | $29,367,000 |
| Other Properties | $371,205,000 | $395,152,000 | $456,414,000 | $463,706,000 |
| Machinery Furniture Equipment | $328,637,000 | $312,749,000 | $334,601,000 | $318,150,000 |
| Buildings And Improvements | $109,793,000 | $105,079,000 | $124,338,000 | $127,634,000 |
| Land And Improvements | $2,251,000 | $1,985,000 | $4,130,000 | $5,358,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $179,523,000 | $221,611,000 | $167,564,000 | $131,791,000 |
| Work In Process | $11,974,000 | $14,956,000 | $15,488,000 | $12,572,000 |
| Raw Materials | $114,873,000 | $128,574,000 | $134,150,000 | $115,016,000 |
| Capital Lease Obligations | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Employee Benefits | - | - | - | - |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $260,441,000 | $142,447,000 | $143,626,000 | $81,731,000 |
| Operating Activities | ||||
| Operating Cash Flow | $293,221,000 | $181,725,000 | $181,751,000 | $273,058,000 |
| Cash Flow From Continuing Operating Activities | $293,221,000 | $181,725,000 | $181,751,000 | $273,058,000 |
| Operating Gains Losses | $-26,471,000 | $-5,219,000 | $-11,039,000 | $-943,000 |
| Investing Activities | ||||
| Capital Expenditure | $-32,780,000 | $-39,278,000 | $-38,125,000 | $-191,327,000 |
| Investing Cash Flow | $-179,547,000 | $-161,895,000 | $-322,389,000 | $-143,788,000 |
| Cash Flow From Continuing Investing Activities | $-179,547,000 | $-161,895,000 | $-322,389,000 | $-143,788,000 |
| Net Other Investing Changes | $-51,891,000 | $-21,112,000 | $-28,171,000 | $81,136,000 |
| Capital Expenditure Reported | $-32,780,000 | $-39,278,000 | $-38,125,000 | $-191,327,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-175,000,000 | $-225,000,000 | $0 | $-75,000,000 |
| Financing Cash Flow | $-178,460,000 | $108,818,000 | $38,157,000 | $-100,364,000 |
| Cash Flow From Continuing Financing Activities | $-178,460,000 | $108,818,000 | $38,157,000 | $-100,364,000 |
| Net Other Financing Charges | $-102,000 | $-111,584,000 | $-922,000 | $-22,755,000 |
| Net Common Stock Issuance | $-175,000,000 | $-225,000,000 | $0 | $-75,000,000 |
| Other | ||||
| Repayment Of Debt | $-306,250,000 | $-502,688,000 | $-72,250,000 | $-339,625,000 |
| Issuance Of Debt | $300,000,000 | $950,000,000 | $110,000,000 | $330,000,000 |
| End Cash Position | $245,440,000 | $306,763,000 | $178,800,000 | $284,466,000 |
| Beginning Cash Position | $306,763,000 | $178,800,000 | $284,466,000 | $259,496,000 |
| Effect Of Exchange Rate Changes | $3,463,000 | $-685,000 | $-3,185,000 | $-3,936,000 |
| Changes In Cash | $-64,786,000 | $128,648,000 | $-102,481,000 | $28,906,000 |
| Proceeds From Stock Option Exercised | $2,892,000 | $-1,910,000 | $1,329,000 | $7,016,000 |
| Common Stock Payments | $-175,000,000 | $-225,000,000 | $0 | $-75,000,000 |
| Net Issuance Payments Of Debt | $-6,250,000 | $447,312,000 | $37,750,000 | $-9,625,000 |
| Net Long Term Debt Issuance | $-6,250,000 | $447,312,000 | $37,750,000 | $-9,625,000 |
| Long Term Debt Payments | $-306,250,000 | $-502,688,000 | $-72,250,000 | $-339,625,000 |
| Long Term Debt Issuance | $300,000,000 | $950,000,000 | $110,000,000 | $330,000,000 |
| Net Investment Purchase And Sale | $-36,071,000 | $-17,143,000 | $-15,551,000 | $-33,205,000 |
| Net Business Purchase And Sale | $-60,180,000 | $-107,615,000 | $-242,352,000 | $-2,000,000 |
| Sale Of Business | $0 | $43,291,000 | $1,500,000 | $850,000 |
| Purchase Of Business | $-60,180,000 | $-150,906,000 | $-243,852,000 | $-2,850,000 |
| Net PPE Purchase And Sale | $1,375,000 | $23,253,000 | $1,810,000 | $1,608,000 |
| Sale Of PPE | $1,375,000 | $23,253,000 | $1,810,000 | $1,608,000 |
| Change In Working Capital | $-12,927,000 | $-91,984,000 | $-63,068,000 | $25,503,000 |
| Change In Other Working Capital | $-24,302,000 | $-15,254,000 | $-22,413,000 | $-22,334,000 |
| Change In Payables And Accrued Expense | $-16,571,000 | $-19,208,000 | $44,582,000 | $39,816,000 |
| Change In Prepaid Assets | $-4,534,000 | $226,000 | $-983,000 | $1,688,000 |
| Change In Inventory | $47,361,000 | $-64,704,000 | $-60,061,000 | $30,754,000 |
| Change In Receivables | $-14,881,000 | $6,956,000 | $-24,193,000 | $-24,421,000 |
| Changes In Account Receivables | $-14,881,000 | $6,956,000 | $-24,193,000 | $-24,421,000 |
| Other Non Cash Items | $3,935,000 | $-20,666,000 | $3,347,000 | $8,817,000 |
| Stock Based Compensation | $33,827,000 | $29,636,000 | $28,332,000 | $25,583,000 |
| Asset Impairment Charge | $86,546,000 | $2,391,000 | $10,419,000 | $607,000 |
| Deferred Tax | $-714,000 | $-15,698,000 | $-1,013,000 | $4,783,000 |
| Deferred Income Tax | $-714,000 | $-15,698,000 | $-1,013,000 | $4,783,000 |
| Depreciation Amortization Depletion | $111,717,000 | $115,586,000 | $97,215,000 | $93,307,000 |
| Depreciation And Amortization | $111,717,000 | $115,586,000 | $97,215,000 | $93,307,000 |
| Gain Loss On Sale Of PPE | $-26,471,000 | $-5,219,000 | $-11,039,000 | $-943,000 |
| Net Income From Continuing Operations | $97,308,000 | $167,679,000 | $117,558,000 | $115,401,000 |
| Interest Paid Supplemental Data | - | $16,534,000 | $20,901,000 | $13,587,000 |
| Income Tax Paid Supplemental Data | - | $49,293,000 | $52,706,000 | $17,967,000 |
| Provisionand Write Offof Assets | - | - | $9,312,000 | $664,000 |
| Gain Loss On Sale Of Business | - | - | $-2,000,000 | $-382,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $50,000,000 |
| Purchase Of Investment | - | - | - | $-33,205,000 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-22